RIDDLE&CODE
17.3.2022 10:17:06 CET | Business Wire | Press release
The consortium formed by Dyne.org, RIDDLE&CODE and InfoCert has entered the second phase of the European Blockchain Services Infrastructure (EBSI) project and will receive support to further develop and test its multilayered blockchain stack ZENBRIDGE.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220317005181/en/
Led by the European Commission and 29 member countries that collaborate as a European Blockchain Partnership (EBP), EBSI aims to develop highly secure and compliant cross-border public services on a European level. This involves overcoming gaps in the existing blockchain applications and delivering more demanding solutions that reduce environmental footprint and comply with EU legal frameworks such as the GDPR. The second phase of the project was launched on December 20, 2021, and will run until the end of June 2022.
Some use cases include management and exploitation of data, tracking of digital records and the rights associated with them, automation of tasks through smart contracts and development of incentive models through tokenization of both physical and digital assets.
ZENBRIDGE, a state-of-the-art decentralized system, offers distributed, secure execution of smart contracts and is integrated with blockchain frameworks such as BigchainDB, PlanetMINT, Ethereum, Hyperledger Fabric, Hyperledger Sawtooth and Bitcoin. The system is designed to deliver high-velocity performance, ensure sustainability and provide superior levels of data sovereignty as well as interoperability between various blockchain networks and legacy systems.
During this second phase, research and development results will be lab-tested. Based on these outcomes, a minimum of three projects will be selected for the final Phase (2B), which will run for an additional 12 months and result in real-world field testing.
Quotes from the consortium members:
Thomas Fürstner (Founder & CTO, RIDDLE&CODE): “The expertise of our consortium will hopefully convince the European Commission to make use of blockchain technology as a multipurpose tool to secure both the value of digital assets and data. At the ‘layer zero’, RIDDLE&CODE will work to connect productive machines and sensors with the security of banking-grade backends. This will allow us to establish trusted digital product passports for physical items in motion across Europe and ensure compliance with the European regulatory frameworks in a transparent way.”
Denis “Jaromil” Roio , (Founder and CTO of Dyne.org): “In our success within the EBSI procurement process, we see a big opportunity to provide the European ICT industry with environmentally sustainable solutions that are free and open to community-based adoption models. We leverage cryptography beyond some common financial sector use cases, making it easy to retrofit and recycle legacy infrastructure. Our solution is free from the speculation and waste of crypto-markets, supports computation on low-power embedded hardware and supports future-proof building blocks that are quantum-resistant. With the ZENBRIDGE stack, a developer can go from a smart contract to a ready-to-use wallet app implementation for digital product passports in a week.”
Carmine Auletta (Chief Strategy and Innovation Officer, InfoCert - Tinexta Group): “We’re pleased with the results achieved by the consortium in Phase 1 and proud of the support and trust placed in us to further develop the project in its second phase. Distributed Ledger Technologies will play an important role in the EU digital market and a key component to their market uptake will inevitably be played by their Governance & Trust Framework. Our consortium partners have demonstrated extraordinary technical expertise in distributed ledger technologies, while InfoCert has very distinctive experience in creating Trust Frameworks. Joining forces has proved crucial to ZENBRIDGE’s success.”
About RIDDLE&CODE
RIDDLE&CODE is Europe’s leading company for blockchain interface solutions. The company develops hardware and software stacks that combine the security of smart cards with blockchain and the Internet of Things (IoT). Together with its tier-one clients and partners, which include Daimler Mobility, BMW, Wien Energie and leading Dutch crypto exchange LiteBit, RIDDLE&CODE brings new business models to the fintech, energy, mobility and materials industries.
More information: www.riddleandcode.com
About Dyne.org
Dyne.org is a non-profit foundation dedicated to free and open-source software and community development with 20 years of expertise in developing applications used worldwide. With the motto “we are free to share code and we code to share freedom”, its projects include independent streaming software for free speech, privacy tools for activists and GNU/Linux distributions.
More information: dyne.org
About InfoCert
InfoCert, Tinexta Group, is the largest European certification authority, active in over twenty countries. The company provides services in digitisation, eDelivery, Digital Signature and digital preservation of documents and is an accredited AgID digital identity operator in the area of SPID (Public System for the management of Digital Identity). The company holds a 60% stake in CertEurope, the biggest certification authority in France; a 51% stake in Camerfirma, one of the principal Spanish certification authorities; a 16.7% stake in Authada, a leading-edge German Identity Provider; and 80% of Sixtema S.p.A.
More information: infocert.digital
View source version on businesswire.com: https://www.businesswire.com/news/home/20220317005181/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom